Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.

Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A.

Clin Pharmacol Ther. 2019 Oct 30. doi: 10.1002/cpt.1661. [Epub ahead of print] No abstract available.

PMID:
31664715
2.

Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.

Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN.

Clin Pharmacol Ther. 2019 Sep 24. doi: 10.1002/cpt.1641. [Epub ahead of print]

PMID:
31549389
3.

Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation.

Hicks JK, McLeod HL.

Biomark Med. 2019 Aug;13(12):987-990. doi: 10.2217/bmm-2019-0228. Epub 2019 Aug 6. No abstract available.

4.

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.

Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshees AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC; IGNITE Network.

Genet Med. 2019 Oct;21(10):2255-2263. doi: 10.1038/s41436-019-0484-3. Epub 2019 Mar 21.

5.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA.

PLoS One. 2018 Nov 27;13(11):e0208097. doi: 10.1371/journal.pone.0208097. eCollection 2018.

6.

Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.

Hicks JK, Henderson-Jackson E, Duggan J, Joyce DM, Brohl AS.

Diagn Pathol. 2018 Oct 12;13(1):77. doi: 10.1186/s13000-018-0759-z.

7.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18.

PMID:
30228210
8.

Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network.

Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, Holmes AM, Kanuri SH, Madden EB, Musty MD, Orlando L, Pratt VM, Ramos M, Wu R, Ginsburg GS.

Genet Med. 2019 Jul;21(7):1670. doi: 10.1038/s41436-018-0280-5.

9.

Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.

Hicks JK, Boyle T, Albacker LA, Madison R, Frampton G, Creelan BC.

J Thorac Oncol. 2018 Aug;13(8):e148-e150. doi: 10.1016/j.jtho.2018.03.028. No abstract available.

10.

Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network.

Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, Holmes AM, Kanuri SH, Madden EB, Musty MD, Orlando L, Pratt VM, Ramos M, Wu R, Ginsburg GS.

Genet Med. 2019 Mar;21(3):743-747. doi: 10.1038/s41436-018-0080-y. Epub 2018 Jul 12. Erratum in: Genet Med. 2018 Aug 29;:.

11.

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.

Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH.

Contemp Clin Trials. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10.

12.

Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring.

Ryan TP, Morrison RD, Sutherland JJ, Milne SB, Ryan KA, Daniels JS, Misra-Hebert A, Hicks JK, Vogan E, Teng K, Daly TM.

PLoS One. 2017 Sep 28;12(9):e0185471. doi: 10.1371/journal.pone.0185471. eCollection 2017.

13.

Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.

Hicks JK, Saller J, Wang E, Boyle T, Gray JE.

Lung Cancer. 2017 Sep;111:135-138. doi: 10.1016/j.lungcan.2017.06.015. Epub 2017 Jun 23.

PMID:
28838384
14.

Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care.

Hicks JK, Shealy A, Schreiber A, Coleridge M, Noss R, Natowicz M, Moran R, Moss T, Erwin A, Eng C.

Clin Transl Sci. 2018 Jan;11(1):71-76. doi: 10.1111/cts.12493. Epub 2017 Jul 27.

15.

Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory.

Vo TT, Bell GC, Owusu Obeng A, Hicks JK, Dunnenberger HM.

Pharmacotherapy. 2017 Sep;37(9):1014-1022. doi: 10.1002/phar.1985. Epub 2017 Sep 3. Review.

PMID:
28699700
16.

Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.

Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL.

J Invest Dermatol. 2017 Sep;137(9):2021-2023. doi: 10.1016/j.jid.2017.05.010. Epub 2017 May 23. Review. No abstract available.

17.

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA.

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14. Review. No abstract available.

18.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.

Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.

PMID:
28235141
19.

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM.

Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 8.

20.

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC.

Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13. No abstract available.

21.

Integrating pharmacogenomics into electronic health records with clinical decision support.

Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM.

Am J Health Syst Pharm. 2016 Dec 1;73(23):1967-1976. Review.

22.

Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services.

Hicks JK, Stowe D, Willner MA, Wai M, Daly T, Gordon SM, Lashner BA, Parikh S, White R, Teng K, Moss T, Erwin A, Chalmers J, Eng C, Knoer S.

Pharmacotherapy. 2016 Aug;36(8):940-8. doi: 10.1002/phar.1786. Epub 2016 Jul 20.

PMID:
27312955
23.

Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.

Hicks JK, Gonzalez BE, Zembillas AS, Kusick K, Murthy S, Raja S, Gordon SM, Hanna R.

Pharmacogenomics. 2016 May;17(7):663-7. doi: 10.2217/pgs-2015-0014. Epub 2016 May 4.

PMID:
27143031
24.

Should thiopurine methyltransferase (TPMT) activity be determined before prescribing azathioprine, mercaptopurine, or thioguanine?

DiPiero J, Teng K, Hicks JK.

Cleve Clin J Med. 2015 Jul;82(7):409-13. doi: 10.3949/ccjm.82a.14106. No abstract available.

25.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29. Review.

26.

To the Editor: Clinical utility of warfarin pharmacogenomics.

Smith DM, Cristiani C, Teng KA, Hicks JK.

Cleve Clin J Med. 2015 May;82(5):268-9. doi: 10.3949/ccjm.82c.05001. No abstract available.

27.

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells.

Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi RK, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, Fan Y, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeldt L, Mullighan CG, den Boer ML, Pieters R, Jeha S, Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui CH, Myers RM, Guy RK, Kanneganti TD, Relling MV, Evans WE.

Nat Genet. 2015 Jun;47(6):607-14. doi: 10.1038/ng.3283. Epub 2015 May 4.

28.

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, Panetta JC, Pei D, Scott JR, Molinelli AR, Broeckel U, Bhojwani D, Evans WE, Relling MV.

Pharmacogenomics. 2014 Jun;15(8):1065-78. doi: 10.2217/pgs.14.53.

29.

Cleveland Clinic's Center for personalized healthcare: setting the stage for value-based care.

Teng K, DiPiero J, Meese T, Doerr M, Leonard M, Daly T, Lacbawan F, Chalmers J, Stowe D, Knoer S, Hicks JK.

Pharmacogenomics. 2014 Apr;15(5):587-91. doi: 10.2217/pgs.14.31.

PMID:
24798715
30.

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.

Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 May;95(5):499-500. doi: 10.1038/clpt.2014.38. Epub 2014 Feb 21.

31.

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.

Hicks JK, Swen JJ, Gaedigk A.

Curr Drug Metab. 2014 Feb;15(2):218-32. Review.

PMID:
24524666
32.

ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.

Wang L, Yang H, Palmbos PL, Ney G, Detzler TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, Hicks JK, Helchowski CM, Prasad J, Lawrence TS, Xu L, Yu X, Canman CE, Ljungman M, Simeone DM.

Cancer Res. 2014 Mar 15;74(6):1778-88. doi: 10.1158/0008-5472.CAN-13-2289. Epub 2014 Jan 27.

33.

Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.

Ladd B, Ackroyd JJ, Hicks JK, Canman CE, Flanagan SA, Shewach DS.

DNA Repair (Amst). 2013 Dec;12(12):1114-21. doi: 10.1016/j.dnarep.2013.10.008. Epub 2013 Nov 11.

34.

Development and use of active clinical decision support for preemptive pharmacogenomics.

Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM.

J Am Med Inform Assoc. 2014 Feb;21(e1):e93-9. doi: 10.1136/amiajnl-2013-001993. Epub 2013 Aug 26.

35.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.

Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group, Shuldiner AR, Vesely M, Robinson SW, Ambulos N Jr, Stass SA, Kelemen MD, Brown LA, Pollin TI, Beitelshees AL, Zhao RY, Pakyz RE, Palmer K, Alestock T, O'Neill C, Maloney K, Branham A, Sewell D, Relling MV, Crews K, Hoffman J, Cross S, Haidar C, Baker D, Hicks JK, Bell G, Greeson F, Gaur A, Reiss U, Huettel A, Cheng C, Gajjar A, Pappo A, Howard S, Hudson M, Pui CH, Jeha S, Evans WE, Broeckel U, Altman RB, Gong L, Whirl-Carrillo M, Klein TE, Sadee W, Manickam K, Sweet KM, Embi PJ, Roden D, Peterson J, Denny J, Schildcrout J, Bowton E, Pulley J, Beller M, Mitchell J, Danciu I, Price L, Pereira NL, Weinshilboum R, Wang L, Johnson JA, Nelson D, Clare-Salzler M, Elsey A, Burkley B, Langaee T, Liu F, Nessl D, Dong HJ, Lesko L, Freimuth RR, Chute CG.

Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19. No abstract available.

36.

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 May;93(5):402-8. doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16. Review.

37.

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.

Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 Apr;93(4):324-5. doi: 10.1038/clpt.2013.4. Epub 2013 Jan 17. No abstract available.

38.

A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record.

Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C, Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV.

Clin Pharmacol Ther. 2012 Nov;92(5):563-6. doi: 10.1038/clpt.2012.140. Epub 2012 Sep 19. No abstract available.

39.

Pharmacogenomics and individualized medicine: translating science into practice.

Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE.

Clin Pharmacol Ther. 2012 Oct;92(4):467-75. doi: 10.1038/clpt.2012.120. Epub 2012 Sep 5.

40.

Concordance of DMET plus genotyping results with those of orthogonal genotyping methods.

Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, Hicks JK, Stewart CF, Kawedia JD, Ramsey LB, Liu C, Evans WE, Relling MV, Broeckel U.

Clin Pharmacol Ther. 2012 Sep;92(3):360-5. doi: 10.1038/clpt.2012.95. Epub 2012 Aug 8.

41.

Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.

Hicks JK, Shelton CM, Sahni JK, Christensen ML.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):943-51. doi: 10.1345/aph.1R116. Epub 2012 Jul 24.

PMID:
22828970
42.

REV1 and polymerase ζ facilitate homologous recombination repair.

Sharma S, Hicks JK, Chute CL, Brennan JR, Ahn JY, Glover TW, Canman CE.

Nucleic Acids Res. 2012 Jan;40(2):682-91. doi: 10.1093/nar/gkr769. Epub 2011 Sep 16.

43.

Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links.

Hicks JK, Chute CL, Paulsen MT, Ragland RL, Howlett NG, Guéranger Q, Glover TW, Canman CE.

Mol Cell Biol. 2010 Mar;30(5):1217-30. doi: 10.1128/MCB.00993-09. Epub 2009 Dec 22.

44.

Psoralen-induced DNA interstrand cross-links block transcription and induce p53 in an ataxia-telangiectasia and rad3-related-dependent manner.

Derheimer FA, Hicks JK, Paulsen MT, Canman CE, Ljungman M.

Mol Pharmacol. 2009 Mar;75(3):599-607. doi: 10.1124/mol.108.051698. Epub 2008 Dec 8.

45.

Balancing quality and cost for Adult Tobacco Telephone Surveys.

Fernandez BM, Hannah KM, Wallack RS, Hicks JK, Gorrigan AM, Mariolis P.

Am J Health Behav. 2007 May-Jun;31(3):284-96.

PMID:
17402868
48.
49.

Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.

Lepper ER, Hicks JK, Verweij J, Zhai S, Figg WD, Sparreboom A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jul 5;806(2):305-10.

PMID:
15171944

Supplemental Content

Loading ...
Support Center